Perspectum

Pancreatic disease is often detected late, and distinguishing between conditions remains a clinical challenge. At #SAR2026, we’re sharing new research exploring how standardised T1 mapping may help address both. 📄 Detecting subclinical pancreatic involvement T1 mapping identifies early changes in IgG4-SC/AIP and helps differentiate from PSC 📄 Understanding risk pathways Fibro-inflammation measured via T1 mapping shows association with pancreatic cancer in a @UK Biobank study Presented by Michele Pansini, VP, Radiological Solutions, this work highlights how quantitative imaging can support earlier identification, clearer differentiation, and improved understanding of disease progression. Attending Society of Abdominal Radiology 2026? We’d be glad to connect and discuss the findings. #Perspectum #AbdominalRadiology #PancreaticCancer #MedicalImaging #RadiologyResearch #QuantitativeImaging

A change on the scale only tells part of the story. Our latest blog, written by Magdalena Nowak and Helena Thomaides Brears published with Springer Nature Research Communities “Beyond the Scales: What MRI Reveals When Weight Changes,” looks at newly published research showing how MRI can reveal what weight alone cannot: changes in visceral fat, liver fat, and muscle. Drawing on data from more than 3,000 UK Biobank participants, the study uses quantitative MRI to assess how body fat and muscle behave as weight shifts. The results underscore the value of MRI in providing a more complete picture of metabolic health and have direct implications for how we design obesity clinical trials, what we measure, how we power studies, and what we're missing if we rely on the scales alone. “This study aligns with our previous research showing that DXA and MRI diverge considerably when tracking muscle change. In an era of fast, drug-driven weight loss, relying on DXA alone risks missing the very changes in body composition that will define the next generation of obesity care.” Professor Louise Thomas - University of Westminster Read the blog: communities.springernature.com/posts/beyond-t… #Perspectum #MetabolicHealth #BodyComposition #ClinicalResearch #ObesityResearch #ImagingBiomarkers #PrecisionMedicine

For patients with chronic liver disease, understanding what is happening in their liver is often as important as knowing what to do next. LiverMultiScan reports are designed to make complex quantitative MRI data accessible, without oversimplifying the science behind it. The report provides a holistic view of liver health by presenting key markers of disease, including disease activity measured using corrected T1 (cT1), liver fat fraction (PDFF), and liver iron concentration. Each report includes clinically validated reference ranges to support physician risk assessment and clinical decision-making. It is designed with both patients and referring physicians in mind: intuitive and easily interpreted by referring physicians. That clarity matters to patients: “This visual clarity is just stunning, and so easy to understand.” – Patient “It’s encouragement to keep going with the lifestyle I’ve been leading.” – Patient This impact is supported by evidence. McKay et al. (Journal of Patient-Reported Outcomes, 2021) demonstrated that LiverMultiScan reports improve patient understanding and engagement, helping to motivate sustained lifestyle change alongside clinical management. Unlock access to see how LiverMultiScan Reports are used in practice: t8glx.share.hsforms.com/2ZXFYPFqBTjqJ9… 👉 Learn more about how how LiverMultiScan reports deliver quantitative, clinically validated insight: perspectum.com/our-products/l… #Perspectum #LiverMultiScan #Hepatology #Radiology #ChronicLiverDisease #QuantitativeMRI

Perspectum is heading to Hanson Wade's 8th Annual CKD Summit. Chronic kidney disease care is moving fast. Health systems and clinical teams are looking for earlier, clearer insight to support smarter pathways and more confident decision-making. 📅 March 16–18 📍 Boston, MA Our team will be on site: Caitlin Langford, Senior Director of Product Khant Tin, Business Development Manager If you’re attending, we would love to connect and compare notes on: Where CKD pathways are heading and the biggest unmet needs How advanced imaging can support more informed clinical decisions Partnership opportunities that help accelerate clinical trials 📧 Arrange a meeting mailto:Pharma.Buisness.Development@perspectum.com?subject=Meeting%20Request&body=Hello%0D%0A #Perspectum #CKDSummit #ChronicKidneyDisease #MedicalImaging #HealthcareInnovation #KidneyHealth

We were honoured to welcome Louise Upton, the Lord Mayor of Oxford, to Perspectum and the Oxford Community Diagnostic Centre this week. The visit provided an opportunity to introduce Perspectum’s mission and to showcase the vital role the Oxford Community Diagnostic Centre plays in delivering accessible, high-quality diagnostic services to the local community. We also shared more about our ongoing initiatives, including how advanced imaging and data-driven insights are helping to transform patient pathways and support earlier, more accurate diagnosis. Thank you to the Lord Mayor for taking the time to learn more about our work and the impact innovation in diagnostics can have across Oxford and beyond. #Perspectum #Oxford #CommunityDiagnosticCentre #HealthcareInnovation #MedicalImaging #Diagnostics #HealthTech #NHS #OxfordCommunity

Perspectum is pleased to be heading to the Society of Abdominal Radiology (SAR) Annual Meeting 2026, 📅 March 15–20 📍 Fajardo, Puerto Rico SAR is a key forum for advancing abdominal imaging, and we’re excited to connect with leaders across radiology and industry to discuss how quantitative imaging can help: 🔵 Strengthen decision-making and care pathways in clinical practice 🔵 Support imaging strategy for trials, including endpoint selection and longitudinal monitoring 🔵 Enable more consistent, scalable insights for therapeutic development Book a meeting with our team onsite: Michele Pansini, VP of Radiological Solutions, Pharma meetings.hubspot.com/michele-pansin… Balaji Ganeshan, Consultant meetings.hubspot.com/balaji-ganesha… If you’re attending SAR and would like to explore collaboration across clinical or pharma solutions, we’d welcome the conversation. #Perspectum #SAR2026 #AbdominalRadiology #MedicalImaging #ClinicalResearch #Pharma

Liver disease isn’t staying in silos; steatosis and cholestasis are increasingly intersecting in real-world patients, and clinical pathways are evolving fast. Perspectum will be attending the American Association for the Study of Liver Diseases (AASLD) 2026 Emerging Topic Conference: Unified Frontiers in Liver Disease, Treating Steatosis, Cholestasis and Beyond. 📅 March 13–15 📍 Four Seasons, Las Vegas, Nevada On-site: Carlos M Duncker, MD, PhD, Senior Medical Affairs Director We’re looking forward to discussions on: 🔵 How the evidence base is evolving across steatotic liver disease, cholestatic conditions, and overlap phenotypes 🔵 Risk stratification and what “progression” should mean in practice 🔵 Emerging perspectives on clinical trial endpoints and real-world implementation Attending and open to a conversation on clinical insights, emerging evidence, or collaboration? 📩 mailto:Carlos.Duncker@perspectum.com?subject=AASLD%20Meeting%20Request&body=Hi%20Carlos%2C Please get in touch with any questions or interests! #Perspectum #AASLD #Hepatology #LiverDisease #SteatoticLiverDisease #MASLD h#Cholestasis

Childhood obesity is not only a metabolic risk. It can also mask silent liver dysfunction. Perspectum is pleased to be attending the Novo Nordisk Foundation Science Cluster Conference: Prevention of Childhood Obesity: Body, Brain & Society. 📅 March 16–20 📍 Favrholm Campus, Hillerød, Denmark. Luis Felipe Cardiel, Product & Market Strategy Lead, will represent Perspectum and present our research poster: “Quantitative MRI identifies undiagnosed liver dysfunction in Mexican children living with obesity.” As the global burden of pediatric metabolic disease continues to grow, scalable and patient-friendly imaging biomarkers are becoming increasingly relevant to clinical trials and drug development, with potential applications in early detection, patient stratification, and longitudinal assessment of metabolic health. If you are attending, we would welcome the opportunity to connect and explore how quantitative imaging can support biomarker strategy, endpoint generation, and earlier data-driven intervention in pediatric metabolic disease. Book a meeting with our team onsite: meetings.hubspot.com/luis-felipe-ca… #ChildhoodObesity #MetabolicHealth #PrecisionMedicine #PediatricResearch #ImagingBiomarkers #PreventionScience

Precision medicine must be precise for women. This International Women’s Day, under the theme “Give to Gain,” we’re reflecting on what progress in women’s health truly requires: giving space to women’s data, giving weight to women’s symptoms, and giving clinicians better tools. Because what we collectively gain is powerful: • earlier answers • clearer risk assessment • better-informed monitoring over time Conditions such as HFpEF, which is more common in women and frequently under-recognised, illustrate that cardiovascular risk is dynamic rather than static. Disease stage and severity significantly influence outcomes, with progression associated with substantially worse morbidity and mortality. The analysis of UK Biobank data, presented by Dr Masliza Mahmod at ESC Congress 2025, highlighted how advancing HFpEF stage is associated with markedly increased risk of major adverse cardiovascular event, reinforcing the importance of earlier identification and more precise risk stratification. At Perspectum, we’re advancing noninvasive, quantitative imaging that supports clinicians with objective insights, helping guide earlier identification, risk stratification, and monitoring over time. Progress happens when research, technology, clinicians, and patients work in partnership. Today, we’re celebrating the women advancing healthcare in clinics, research, industry, and through lived experience, and recommitting to the shared effort needed to ensure women are seen, heard, and supported across the full spectrum of health. #Perspectum #InternationalWomensDay #IWD2026 #WomensHealth #PrecisionMedicine #HealthEquity

Perspectum is proud to attend and sponsor The Liver Forum, a multi-stakeholder consortium advancing drug development and novel regulatory approaches in MASH and liver fibrosis. Through quantitative MRI biomarkers such as corrected T1 and PDFF, alongside digital pathology and endoscopy central reads, we deliver reliable, objective endpoints that strengthen MASH clinical development and accelerate more efficient, data-driven trials. 📅 March 6–7 📍 Reston, Virginia Andrea Dennis, SVP Translational Science, and Caitlin Langford, Senior Director of Product, Pharma, will be onsite to engage with sponsors, biotech teams, and clinical research partners. We work with trial sponsors to generate validated, quantitative imaging biomarkers and integrate them into clinical development programs, from early-phase studies through submission planning, helping teams strengthen their endpoint strategies and support regulatory discussions with objective data. The Liver Forum is an important setting for collaborative scientific exchange across industry, academia, and regulators. If you are attending and would like to discuss emerging science in imaging biomarkers and their role in clinical development, we would welcome the conversation. #Perspectum #LiverForum #DrugDevelopment #ClinicalTrials #ImagingBiomarkers #PrecisionMedicine

Not all weight loss is metabolically equal. And weight gain may be even more asymmetric. Standing on the scale tells you how much weight changed. It does not tell you where that change occurred. That distinction matters. In a longitudinal study published in @Nature's International Journal of Obesity, of approximately 3,000 UK Biobank participants with repeat abdominal MRI over 2.5 years, we quantified how fat and muscle compartments shift with natural weight change. These data were captured before widespread GLP-1 use. Among individuals who lost 10–15% of body weight: • Liver fat reduced by ~30% • Visceral fat reduced by ~40% In contrast, similar weight gain was associated with: • ~70% increase in liver fat • ~60% increase in visceral fat Muscle behaved differently. It did not increase with weight gain and declined even with modest 2–5% weight loss. Intramuscular fat accumulated with weight gain and showed limited reduction, even at higher levels of weight loss. The implication is clear: body weight alone is an incomplete endpoint. As GLP-1 therapies drive unprecedented weight reduction, compartment-level imaging biomarkers will be critical for: • Selecting meaningful clinical trial endpoints • Accurately powering studies • Understanding tissue-specific effects beyond BMI This large-scale, pre-incretin reference dataset provides an objective baseline for interpreting metabolic change in the modern therapeutic era. As Professor Lee Kaplan notes: "GI hormone-based therapies are rapidly expanding effective treatment options for people with obesity and MASLD. This study of more than 3,000 adults from the general population uses MRI to quantify the impact of weight change on body composition and liver fat. The findings provide a real-world benchmark for what clinicians may expect from weight loss or gain, and an important reference point as we enter this new therapeutic era." Read the full paper: nature.com/articles/s4136… #Perspectum #PrecisionMedicine #ClinicalTrials #ImagingBiomarkers #MetabolicHealth #DataDrivenHealthcare

On World Obesity Day, one thing is clear: Obesity is not defined by weight alone. It is a chronic, systemic disease shaped by biology and multi-organ dysfunction. Yet BMI and risk scores still dominate how we assess metabolic health. In our whitepaper, Gaining Clinically Relevant Insights in Obesity and Metabolic Diseases through Advanced Imaging Solutions, we explore why organ-level insight matters, and how multi-organ MRI can reveal changes in visceral fat, muscle, and liver health that weight alone may miss Obesity intersects with type 2 diabetes, cardiovascular disease, and liver dysfunction. Seeing how these conditions affect the body across organs is essential for guiding care with precision. Because better insight enables better decisions. Read the full paper: perspectum.com/wp-content/upl… #Perspectum #WorldObesityDay #MetabolicHealth #PrecisionMedicine

Rare Disease Day reminds us that in rare conditions, progress is rarely dramatic. It is measured. Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease affecting approximately 1 in 100,000 people. For people living with PSC, progression can be unpredictable. Meaningful advances depend on sustained research and increasingly precise ways of measuring structural change over time. Breakthroughs in rare diseases are seldom singular moments. They are built through longitudinal data, reproducible measurement, and careful refinement of evidence. At Perspectum, our work in PSC has focused on bringing quantitative assessment to MRCP, enabling objective evaluation of the biliary tree. In longitudinal research, quantitative MRCP has demonstrated measurable structural progression. In one published case study: • Total number of strictures increased from 4 to 13 • Total number of ducts increased from 25 to 53 • Biliary tree volume increased from 5.5 mL to 12.0 mL Published evidence has also shown that having more than 26% of ducts within the 3–5 mm range is associated with a greater likelihood of adverse clinical events, and that higher stricture burden is linked to increased risk. These findings highlight how structural progression may be captured quantitatively, beyond what traditional risk scores alone detect. Recent peer-reviewed publications further explore the prognostic and clinical relevance of quantitative MRCP in PSC: journals.lww.com/jcat/fulltext/… sciencedirect.com/science/articl… onlinelibrary.wiley.com/doi/10.1111/ap… 🔗 Explore our full MRCP research portfolio: perspectum.com/publications/?… On Rare Disease Day 2026, we recognise that advancing rare disease research is a collective effort, powered by people, strengthened by data, and built study by study. #Perspectum #RareDiseaseDay #PSC #RareDiseaseResearch #MedicalImaging #QuantitativeImaging

We’re proud to be attending the 6th Annual Liver Connect Conference in Chula Vista, California, a leading forum dedicated to advancing liver disease care through collaboration, innovation, and clinical excellence. Our Medical Director, Dr. Prashant Pandya, will be on-site engaging with hepatology leaders and exploring the latest breakthroughs in chronic liver disease management, from MASLD to cholestatic and alcohol-related liver disease. As the field continues to evolve, so does the need for precise, non-invasive tools that can transform clinical pathways and improve patient outcomes. We’re looking forward to meaningful conversations about what’s next for hepatology. Attending? Let’s connect and explore how we can drive greater impact together. #Perspectum #LiverConnect #Hepatology #LiverDisease #HealthcareInnovation

We are delighted to share that our latest research is featured on the front cover of the @bmj_latest's Journal of Clinical Pathology, March 2026, alongside an editorial discussing our work. Our paper introduces one of the first AI systems to automatically detect portal tracts and quantify the spatial distribution of inflammation and steatosis in liver biopsies. While aligning with manual scoring, the system identified a higher inflammatory burden in AIH compared to MASLD/MASH despite similar grades, highlighting the value of anatomy-anchored, spatially resolved AI. The accompanying editorial explores why AI that “thinks like a pathologist”, using landmark detection and zone-aware analysis, may shape the future of liver pathology. Paper: jcp.bmj.com/content/79/3/1… Editorial: jcp.bmj.com/content/79/3/1… Cover: jcp.bmj.com/content/79/3?c… #Perspectum #LiverDisease #ArtificialIntelligence #DigitalPathology #AIinHealthcare #MedicalInnovation

We’re presenting new data at ECCO on how AI is advancing objective assessment in Ulcerative Colitis, from endoscopy to histology. 🎤 Digital Oral Presentation (DOP095) 📅 Friday 20th | Session starts 8:30am AI inflammation & architectural model differentiating active vs remission UC across histological scoring systems. 📌 Posters P0005 – Improving reader alignment in histological scoring P0278 – Predicting histological activity using AI-driven endoscopic scoring P0554 – AI assessment from endoscopy videos using MES & UCEIS Together, this work explores how AI can support more consistent, scalable and predictive UC disease activity assessment. If you’re attending ECCO, we welcome the discussion. #Perspectum #ECCO26 #UlcerativeColitis #InflammatoryBowelDisease #IBD #Gastroenterology #MedicalInnovation

We are pleased to share that Perspectum will be participating in the Radiology AI Summit 2026, with Michele Pansini, VP Radiological Solutions, Pharma, joining as a panelist. The summit brings together leaders across radiology, artificial intelligence, and medical technology to explore how AI is transforming imaging, diagnostics, and patient care. We look forward to contributing to the discussion and sharing insights on advancing clinically meaningful, evidence-driven AI in radiology. If you are attending #RAIS26, we would welcome the opportunity to connect. Thank you to the London Institute for Healthcare Engineering for convening what promises to be an important and forward-looking event. #Perspectum #AIinRadiology #MedTechInnovation #HealthcareAI

LiverMultiScan is a non-invasive, quantitative MRI solution providing a comprehensive assessment of liver health, supporting identification, risk stratification, prognostication, and monitoring of chronic liver disease. Designed for clinical decision-making, LiverMultiScan offers: • Safe and non-invasive assessment A quick, pain-free, non-contrast method for liver assessment • Early identification of liver disease: LiverMultiScan enables early identification of at-risk individuals, guiding preventative strategies • Reliable monitoring Supports longitudinal monitoring of treatment response and enables early detection of clinically meaningful change using reliable, repeatable, and reproducible metrics • Prognostic insight Supports risk stratification through markers linked to liver-related and cardiovascular outcomes • Patient-friendly reporting Clear, intuitive reports that improve understanding and patient engagement Monitoring meaningful change in chronic liver disease remains a clinical challenge. Due to the excellent repeatability of LiverMultiScan's cT1 and Liver Fat Fraction (PDFF) measurements, these metrics have shown great value in monitoring treatment response. Explore LiverMultiScan further and request a demo: perspectum.com/our-products/l… #Perspectum #HealthcareInnovation #LiverMultiScan #NonInvasiveDiagnostics

As the IBD community gathers at ECCO, a familiar challenge remains at the centre of both research and clinical trials: How do we make IBD histology more objective, reproducible, and scalable, without losing clinical relevance? At Perspectum, we’re supporting Phase I–III GI trials by combining centralised endoscopy and pathology with AI-based analysis, enabling a more objective readout of histological disease activity. Our latest research shows how we now measure 40+ distinct inflammatory and architectural metrics, providing quantitative insight that goes beyond the limitations of manual human reading alone. This level of granularity is increasingly critical for differentiating treatment effects in today’s competitive IBD trial landscape. Across recent gastroenterology congresses, our work has demonstrated how deep learning can: Quantify biopsy quality issues that confound both human and AI readers Reduce subjectivity and inter-observer variability in histological assessment Deliver more consistent, trial-ready histology endpoints If you’re attending ECCO in Stockholm and would like a brief conversation on IBD pathology, digital histology, or clinical trial applications, connect with Phil Wakefield or Nicholas Hyde. #Perspectum #IBD #ECCO #DigitalPathology #ClinicalTrials #AIinHealthcare

We are proud to share that our co-founder, Sir Michael Brady, has been elected to the National Academy of Engineering (NAE). Election to the NAE is among the highest professional distinctions awarded to an engineer. Michael has been recognised for his contributions to vision-based robotics and image-based medical diagnosis and treatment. His pioneering work helped lay the foundations for how artificial intelligence is applied to medical imaging today, supporting earlier disease detection, improving diagnostic precision, and enabling more informed clinical decision-making. This recognition reflects not only an extraordinary career, but the lasting impact of engineering innovation on healthcare. Congratulations, Michael! #Perspectum #NationalAcademyofEngineering #HealthcareInnovation